



### **AIFA PUBLISHES CTS OPINION ON MONOCLONAL ANTIBODIES**

AIFA publishes the opinion of its Scientific-Technical Committee (CTS), which met in extraordinary session on 2, 3 and 4 February 2021, on the use of monoclonal antibodies. As stated in the opinion, adopted on 4 February 2021, *"the CTS, while considering data immaturity and the consequent uncertainty as for the extent of the benefit offered by these drugs, believes, by a majority, that in exceptional cases and in view of the emergency situation, it may still be appropriate to offer a therapeutic option to non-hospitalized subjects who, despite having a mild/moderate disease, are at high risk of developing a severe form of COVID-19 with a consequent increase in the probability of hospitalization and/or death. In particular, it is a risk setting for which no standard treatment of proven efficacy is currently available"*.

This opinion, published on the institutional portal, has been provided to verify the possible methods of use of such medicinal products within the NHS.